@inproceedings{inproceedings, title  = {{Vandetanib inhibits both pVEGFR2 and pEGFR at clinically achievable drug levels in preclinical models}},

 url = {{}},

 year = {{2007}},

 month = {{1}},

 author = {{Brave SR and Odedra R and Smith N and James N and Marshall G and Acheson N and Howard Z and Baker D and Jackson L and Hickinson M and Wilkinson R et al}},

 volume = {{6}},

 journal = {{MOLECULAR CANCER THERAPEUTICS}},

 issue = {{12}},

 pages = {{3409S-3409S}},

 note = {{Accessed on 2024/12/22}}}